Caliway receives US FDA clearance to proceed with SUPREME-01 phase 3 study of CBL-514 for reducing abdominal subcutaneous fat: New Taipei City Tuesday, July 29, 2025, 14:00 Hrs [I ...

Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Explore the potential of GLP-1 receptor agonists for rheumatoid arthritis. Learn about their safety, benefits, and what to consider before starting these medications.

There's been plenty of buzz about this class of drug, following publication of a high-profile trial this year. How much do we ...

DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus®DehydraTECH-GLP-1 s ...

CBL-514, Caliway's first-in-class lipolysis drug candidate, has been granted clearance from the U.S. FDA to proceed with SUPREME-01, a global, ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that the first participants with obesity or overweight with at least one weight-related comorbidity have been dosed in its U.S. 12-week ...

These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...

"We are extremely encouraged by the interim results received to date aligned with our primary study endpoint," said Richard Christopher, CEO of Lexaria. "DehydraTECH is continuing to demonstrate ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...